HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Abstract
The identification as cooperating targets of Proviral Integrations of Moloney virus in murine lymphomas suggested early on that PIM serine/threonine kinases play an important role in cancer biology. Whereas elevated levels of PIM1 and PIM2 were mostly found in hematologic malignancies and prostate cancer, increased PIM3 expression was observed in different solid tumors. PIM kinases are constitutively active and their activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing number of common as well as isoform-specific substrates including several cell cycle regulators and apoptosis mediators. PIM1 but not PIM2 seems also to mediate homing and migration of normal and malignant hematopoietic cells by regulating chemokine receptor surface expression. Knockdown experiments by RNA interference or dominant-negative acting mutants suggested that PIM kinases are important for maintenance of a transformed phenotype and therefore potential therapeutic targets. Determination of the protein structure facilitated identification of an increasing number of potent small molecule PIM kinase inhibitors with in vitro and in vivo anticancer activity. Ongoing efforts aim to identify isoform-specific PIM inhibitors that would not only help to dissect the kinase function but hopefully also provide targeted therapeutics. Here, we summarize the current knowledge about the role of PIM serine/threonine kinases for the pathogenesis and therapy of hematologic malignancies and solid cancers, and we highlight structural principles and recent progress on small molecule PIM kinase inhibitors that are on their way into first clinical trials.
AuthorsLaurent Brault, Christelle Gasser, Franz Bracher, Kilian Huber, Stefan Knapp, Jürg Schwaller
JournalHaematologica (Haematologica) Vol. 95 Issue 6 Pg. 1004-15 (Jun 2010) ISSN: 1592-8721 [Electronic] Italy
PMID20145274 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • PIM2 protein, human
  • Proto-Oncogene Proteins
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-pim-1
Topics
  • Amino Acid Sequence
  • Animals
  • Hematologic Neoplasms (enzymology, genetics, therapy)
  • Humans
  • Molecular Sequence Data
  • Neoplasms (enzymology, genetics, therapy)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors, chemistry, genetics)
  • Proto-Oncogene Proteins (antagonists & inhibitors, chemistry, genetics)
  • Proto-Oncogene Proteins c-pim-1 (antagonists & inhibitors, chemistry, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: